An interventional study of FLEBOGRIF in Chronic Venous Insufficiency, CVI, sponsored by Balton Sp.zo.o.. Completed at 4 sites in Poland. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2023-06-18.
Sponsored by Balton Sp.zo.o. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objective of the study is to collect clinical data of patients in whom Flebogrif® will have been used for mechanochemical ablation of incompetent veins in the follow-up period, as related to the safety, clinical effectiveness, properties and advantages of Flebogrif®.
The proposed study is a prospective, multi-centre clinical trial assessing the safety, efficacy and quality of Flebogrif® in a population of patients with the incompetent great saphenous vein, who require surgical treatment.
Balton Sp.zo.o. is the lead sponsor of 7 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Study inclusion criteria:
Study exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Interventions will be performed using Flebogrif catheter.
Device: FLEBOGRIF
The catheter is a device dedicated to mechano-chemical ablation of insufficient veins of the superficial system.
Primary efficacy endpoint: Occlusion rate
Primary efficacy endpoint: Occlusion rate of the great saphenous vein in the treated segment at 3 months
Time frame: 3 months
Primary safety endpoint: Rate of SAE
Primary safety endpoint: Rate of serious adverse events within 30 days after the procedure
Time frame: 30 days after the procedure
Occlusion rate
Occlusion rate of the great saphenous vein at 1, 6, 12, 18 and 24 months
Time frame: 1, 6, 12, 18, 24 months
Number of Participants with no reflux in treated segment of the vein
Number of Participants with no reflux in the treated segment of the great saphenous vein at 1, 3, 6, 12, 18 and 24 months
Time frame: 1, 3, 6, 12, 18, 24 months
Change in quality of life by Aberdeen Varicose Vein Questionnaire
Change in quality of life measured with the use of the Aberdeen Varicose Vein Questionnaire at 12 and 24 months Scale score: 0-100; higher score = worse outcome.
Time frame: 12 and 24 months
Clinical success - changes in rVCSS
Clinical success, defined as change in rVCSS classification (Revised Venous Clinical Severity Score) after 12 and 24 months Scale score 0-30; higher score = worse outcome.
Time frame: 12 and 24 months
Assessment of pain during the procedure
Assessment of pain during the procedure (Visual Analogue Pain Scale, VAPS) ranging from 0 to 10. Pain assessed using the Visual Analogue Scale (range 0-10; 0 = no pain; 2 = mild pain, 4 = nagging, annoying pain; 6 = severe pain; 8 = very severe pain; 10 = unbearable pain).
Time frame: During procedure
Assessment of pain within 0-7 days after the procedure: Visual Analogue Scale
Assessment of pain within 0-7 days after the procedure (VAPS 0-10, daily assessment). Pain assessed using the Visual Analogue Scale (range 0-10; 0 = no pain; 2 = mild pain, 4 = nagging, annoying pain; 6 = severe pain; 8 = very severe pain; 10 = unbearable pain).
Time frame: 0-7 days after procedure
Assessment of the need for analgesic treatment
Assessment of the need for analgesic treatment after the procedure (0-7 days)
Time frame: 0-7 days after procedure
Period needed to resume normal activities
Period needed to resume normal activities
Time frame: up to 2 years after the treatment
Period needed to return to work (sick leave period)
Period needed to return to work (sick leave period)
Time frame: up to 2 years after the treatment
Complications rate
Complications rate including deep vein thrombosis, nerve damage, infections, etc.
Time frame: up to 2 years after the treatment
Ran from Aug 2019 to primary completion in Aug 2021, 24 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Blindness, Cortical
Balton Sp.zo.o.